• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • TBK1 Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • Adenosine Kinase Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

The Contribution of DNA Methyltransferase Inhibitors in Treating Myelodysplastic Syndromes

by Bellbrook Labs / Tuesday, 01 October 2019 / Published in Emerging Targets, Epigenetics
DNA Methyltransferase Inhibitors for MDS

Myelodysplastic syndromes (MDS) are a broad, complex group of cancers characterized by the inability to form mature, healthy blood cells. There are different types with varying degrees of risk associated, making it difficult to diagnose and treat. Additionally, many patients are symptom-free and at an older age where they are likely to have other life-threatening ailments. Although there is no specific known cause, genetics, as well as DNA damaging agents, seem to contribute to these types of cancer. Managing symptoms and progression of the disease is the goal once diagnosed with MDS. This is done via an intense risk stratification system; individuals are either low, intermediate or high risk depending on a specific pattern and degree of cytopenias, serum erythropoietin (sEPO) level, presence of a genetic deletion (del(5q)), marrow cellularity, age and comorbid conditions.1

DNA Methyltransferase Inhibitors for MDS

DNA methylation is an epigenetic reaction that contributes to gene expression; whether a gene is turned on or off. Methylation occurs by the addition of a methyl group to the C5 position of cytosine at CpG dinucleotides catalyzed by the DNA methyltransferase enzyme.2 In several cancers including MDS, genes that regulate growth, differentiation, or apoptosis could become inactivated due to DNA hypermethylation.3 According to Saba et al., multiple genes are hypermethylated in MDS including one that increases during disease progression to acute myeloid leukemia (AML).3

Fortunately for MDS patients, two FDA approved drugs (azacitidine or decitabine) are available as DNA methyltransferase inhibitors, therefore, slowing the effects of hypermethylation. When DNA is replicated in the cell, these hypomethylating agents are capable of incorporating and irreversibly binding to stop DNA methyltransferase from doing so, which ultimately leads to reversing epigenetic suppression of genes.4 These inhibitors have become extremely useful in treating patients with MDS. In fact, once they stop working due to intolerance, resistance, or relapse after a favorable response, there is no approved second-line therapy, and the outlook is poor with a low survival rate.1

DNA Methyltransferase Inhibitors for Other Indications

Turns out, cancer isn’t the only disease in which DNA methyltransferase inhibitors can lend a hand. The epigenetic effects of DNA methylation are seen in an array of biological functions.  Researchers have found exciting potential benefits for cardiovascular disease (CVD) and inflammatory disorders.2 Specifically, Hydralazine (a DNA methyltransferase inhibitor) has been recently FDA approved as an anti-hypertensive drug.2 Although there have been some thrilling findings as of late, more investigation in this area is needed.

High throughput activity assays can be used to find novel drugs for DNA methyltransferase targets. BellBrook’s AptaFluor Methyltransferase Assay directly detects SAH produced by enzymes providing a universal method for inhibitor screening.  Once hits are discovered, the assay can also be used to determine inhibitor potency during SAR campaigns and lead optimization initiatives. New therapeutics could lead to treatments for a variety of diseases including MDS.

Learn About the Methyltransferase Assay

References

  1. Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018. doi:10.1038/s41408-018-0085-4 https://www.nature.com/articles/s41408-018-0085-4
  2. Nicorescu I, Dallinga GM, de Winther MPJ, Stroes ESG, Bahjat M. Potential epigenetic therapeutics for atherosclerosis treatment. Atherosclerosis. 2019;281(October 2018):189-197. doi:10.1016/j.atherosclerosis.2018.10.006. https://www.ncbi.nlm.nih.gov/pubmed/30340764
  3. Saba HI. Decitabine in the treatment of myelodysplastic syndromes. 2007;3(5):807-817. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376088/
  4. Press D. Decitabine in the treatment of acute myeloid leukemia in elderly patients. 2014:53-61. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917925/
  5. Tandon B, Lee Y, Wartman LD, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal. 2016:2023-2036. doi:10.1056/NEJMoa1605949 https://www.ncbi.nlm.nih.gov/pubmed/27959731
Tagged under: AptaFluor SAH Methyltransferase Assay, dna methyltransferase inhibitors

What you can read next

Bound for Life: The First Irreversible Inhibitor of CDK2
Epigenetics: Kinases Can Play Too
The Power of PKM2

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Scientist Studying ALKPK1

    The Role ALPK1 in Health and Disease

    ALPK1 (Alpha Kinase 1) is an atypical serine/th...
  • DHX36 RNA Helicase Unwinds G4 RNA Structures

    Resolving the Many Roles of DHX36

    While most researchers are familiar with canoni...
  • Researcher Studying MAPK14

    MAPK14 in Context

    MAPK14 (or p38 alpha or SAPK2a) is a proline-di...
  • PRMT5 Role with Macrophages

    PRMT5 is Innately Interesting

    PRMT5 is a type II arginine methyltransferase t...
  • IRE1 Proteins in ER

    The Multifaceted Roles of IRE1 Are Unfolding

    IRE1 (Inositol-Requiring Enzyme 1) is one of th...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2021 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP